A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

EaglePicher Medical Power Introduces New Contego 440 mAh Lithium-ion Battery

New Contego® 440: An Implantable & Rechargeable Large-capacity, Small-footprint Cell Utilizing a Proven Chemistry that Has Extensive Cycling Data Across Multiple Medical Customers

EaglePicher® Medical Power, a division of EaglerPicher Technologies, announced today the launch of the all-new Contego® 440 mAh battery, an implantable grade, lightweight, and high-energy-density lithium-ion battery.

According to EaglePicher, the rechargeable off-the-shelf Contego 440 offers superior rate capability and cycle life and is manufactured in a certified ISO13405 facility.

The Contego 440 battery comes in a fully welded hermetically sealed stainless-steel case and can be used across a range of medical applications including neuromodulators, drug pumps, body fluid pumps, and cardiac monitors. The individual battery weighs just 19.1g and carries a voltage range of 3.0 to 4.1V. While the Contego 440 is available off-the-shelf, additional options include custom terminations, application-specific documentation for FDA submission, application-specific testing, custom markings, and custom packaging.

“We’re extremely pleased to introduce the Contego 440 as part of our growing line of mission-critical medical device batteries,” commented Chris Huntington, EaglePicher Medical Power’s President. “The team at EaglePicher Medical Power is committed to developing the latest technology innovations to fuel medical advancement, treatment protocols and improve quality of life. With the new Contego 440, we’ve succeeded in delivering more energy in a small, lightweight cell, while never compromising safety.”

EaglePicher has been at the forefront of implantable medical-grade power solutions for over 25 years. The electrochemistry used in Contego lithium-ion batteries, since 2004, is proven in multiple cell sizes and is remarkably robust, without experiencing a single field failure. Over time, demand has grown for batteries like the new Contego 440, which can do more with less of a physical footprint.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy